Alzheimer’s Drug Development: A Recent Wave of Investment and Innovation Despite the recent approval of two amyloid-targeting therapies for Alzheimer’s disease, investors are continuing to bet on new approaches to tackling the devastating condition. Korsana Biosciences, a newly launched company, has secured $175 million in funding to advance its own amyloid-clearing treatment, KRSA-028. The Persistent … Read more
Unlocking the Mystery of VITT: How a Genetic ‘Unlucky Break’ Led to Safer Vaccine Design For years, a rare but serious side effect shadowed the rollout of adenovirus-vector COVID-19 vaccines: vaccine-induced immune thrombocytopenia and thrombosis (VITT). Now, scientists have pinpointed the precise mechanism behind this condition, offering a pathway to redesign vaccines and prevent similar … Read more
Psilocybin Therapy: A New Dawn for Treatment-Resistant Depression? The landscape of mental health treatment is undergoing a significant shift, with psilocybin emerging as a potential breakthrough for individuals battling treatment-resistant depression (TRD). Compass Pathways recently released promising Phase 3 trial results for COMP360, their investigational psilocybin treatment, potentially paving the way for the second psychedelic-assisted … Read more
FDA Rejection of Disc Medicine’s Bitopertin: A Turning Point for Fast-Tracked Drug Reviews? The Food and Drug Administration (FDA) on Friday rejected bitopertin, a therapy developed by Disc Medicine for the treatment of porphyria, a rare blood disorder causing extreme sensitivity to sunlight. This decision marks the first rejection under FDA Commissioner Marty Makary’s new … Read more
FDA’s Shocking Rejection of Moderna’s Flu Vaccine: A Turning Point for mRNA Technology? The Food and Drug Administration’s (FDA) decision to refuse review of Moderna’s mRNA-based flu vaccine application has sent shockwaves through the pharmaceutical industry. Moderna President Stephen Hoge described the move as “completely shocking,” raising questions about the future of mRNA vaccine development … Read more
The Battle for Affordable GLP-1s: A Turning Point for US Healthcare? The rising cost of prescription drugs continues to dominate healthcare headlines, and a recent petition filed by Public Citizen with the Department of Health and Human Services (HHS) highlights a particularly contentious area: GLP-1 receptor agonists. These medications, like semaglutide (Ozempic, Wegovy) and tirzepatide, … Read more
The Future of HIV Prevention: A Monthly Pill on the Horizon? Patient advocacy groups are already mobilizing, urging pharmaceutical company Merck to ensure global access to a potentially groundbreaking HIV prevention pill, MK-8527. This isn’t just another drug in development; it represents a significant shift in how we approach PrEP (pre-exposure prophylaxis), moving away from … Read more
Future Trends Shaping the Hypochlorous Acid (HOCl) Market Why HOCl Is Gaining Momentum in Healthcare Stabilized hypochlorous acid (HOCl) has emerged as a versatile, non‑toxic solution for wound care, dermatology, eye care, and even disinfection. Its ability to reduce itch, pain, and scarring without harming healthy tissue makes it a preferred alternative to traditional antiseptics. … Read more
Oregon Primate Center Faces Potential Shift to Sanctuary: A Sign of Changing Times in Biomedical Research The Oregon Health & Science University (OHSU) board of directors has authorized negotiations with the National Institutes of Health (NIH) that could dramatically reshape the future of the Oregon National Primate Research Center (ONPRC). The potential outcome? A transition … Read more
FDA Scrutiny Intensifies Compounded Drug Landscape: What’s Next for Wegovy and Beyond? The U.S. Food and Drug Administration is increasing its oversight of compounded drugs, particularly those mimicking popular medications like Novo Nordisk’s Wegovy. A recent warning letter issued to MedisourceRx, a compounding pharmacy owned by Hims & Hers, highlights growing concerns about patient safety … Read more